First Mercantile Trust Co. cut its holdings in shares of Masimo Co. (NASDAQ:MASI) by 32.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 6,074 shares of the medical equipment provider’s stock after selling 2,918 shares during the quarter. First Mercantile Trust Co.’s holdings in Masimo were worth $515,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MASI. SeaCrest Wealth Management LLC purchased a new position in shares of Masimo during the 4th quarter worth $116,000. DekaBank Deutsche Girozentrale grew its holdings in shares of Masimo by 78.3% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock worth $182,000 after purchasing an additional 925 shares during the period. Advisor Group Inc. grew its holdings in shares of Masimo by 38.4% during the 2nd quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 655 shares during the period. Intellectus Partners LLC purchased a new position in shares of Masimo during the 2nd quarter worth $237,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Masimo by 39.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,820 shares of the medical equipment provider’s stock worth $239,000 after purchasing an additional 802 shares during the period. Institutional investors and hedge funds own 82.57% of the company’s stock.

Masimo Co. (MASI) opened at $83.47 on Friday. Masimo Co. has a 12 month low of $75.06 and a 12 month high of $104.71. The stock has a market capitalization of $4,240.13, a PE ratio of 13.21, a P/E/G ratio of 3.12 and a beta of 0.85.

MASI has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a report on Thursday, November 2nd. BidaskClub cut Masimo from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $108.00 target price on shares of Masimo in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $97.17.

In related news, Director Sanford Fitch sold 2,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $93.07, for a total transaction of $186,140.00. Following the transaction, the director now owns 68,249 shares of the company’s stock, valued at approximately $6,351,934.43. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Yongsam Lee sold 5,900 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $88.31, for a total value of $521,029.00. Following the transaction, the executive vice president now directly owns 70,800 shares in the company, valued at approximately $6,252,348. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,098 shares of company stock worth $4,315,261. 16.60% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dailypolitical.com/2018/02/10/masimo-co-masi-shares-sold-by-first-mercantile-trust-co.html.

Masimo Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.